131 related articles for article (PubMed ID: 31898663)
1. A comparison of six fractions per week chemoradiation versus five fractions per week of conventional chemoradiation in carcinoma cervix: A prospective controlled study.
Kumar D; Pradhan S; Choudhary S; Aggarwal LM; Das A; Sarangdhar S; Kaser P; Dewangan S
J Cancer Res Ther; 2019; 15(6):1296-1303. PubMed ID: 31898663
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin Chemoradiotherapy vs Radiotherapy in FIGO Stage IIIB Squamous Cell Carcinoma of the Uterine Cervix: A Randomized Clinical Trial.
Shrivastava S; Mahantshetty U; Engineer R; Chopra S; Hawaldar R; Hande V; Kerkar RA; Maheshwari A; Shylasree TS; Ghosh J; Bajpai J; Gurram L; Gulia S; Gupta S;
JAMA Oncol; 2018 Apr; 4(4):506-513. PubMed ID: 29423520
[TBL] [Abstract][Full Text] [Related]
3. Prospective randomized trial to compare accelerated (six fractions a week) radiotherapy against concurrent chemoradiotherapy (using conventional fractionation) in locally advanced head and neck cancers.
Gupta M; Mahajan R; Kaushal V; Seem RK; Gupta M; Bhattacharyya T
J Cancer Res Ther; 2015; 11(4):723-9. PubMed ID: 26881508
[TBL] [Abstract][Full Text] [Related]
4. Can pure accelerated radiotherapy given as six fractions weekly be an option in locally advanced carcinoma cervix: Results of a prospective randomized phase III trial.
Sharma M; Revannasiddaiah S; Gupta M; Seam RK; Gupta MK; Rastogi M
J Cancer Res Ther; 2016; 12(1):103-8. PubMed ID: 27072219
[TBL] [Abstract][Full Text] [Related]
5. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
[TBL] [Abstract][Full Text] [Related]
6. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
[TBL] [Abstract][Full Text] [Related]
7. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study.
Naik A; Gurjar OP; Gupta KL; Singh K; Nag P; Bhandari V
Cancer Radiother; 2016 Jul; 20(5):370-6. PubMed ID: 27368915
[TBL] [Abstract][Full Text] [Related]
8. Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer.
Cihoric N; Tsikkinis A; Tapia C; Aebersold DM; Zlobec I; Lössl K
Radiat Oncol; 2015 Nov; 10():240. PubMed ID: 26597282
[TBL] [Abstract][Full Text] [Related]
9. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
[TBL] [Abstract][Full Text] [Related]
11. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.
Gandhi AK; Sharma DN; Rath GK; Julka PK; Subramani V; Sharma S; Manigandan D; Laviraj MA; Kumar S; Thulkar S
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):542-8. PubMed ID: 24074927
[TBL] [Abstract][Full Text] [Related]
12. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
[TBL] [Abstract][Full Text] [Related]
13. Significance of concurrent use of weekly cisplatin in carbon-ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix: A propensity score-matched analysis.
Okonogi N; Wakatsuki M; Kato S; Murata H; Kiyohara H; Karasawa K; Ohno T; Tsuji H; Nakano T; Shozu M;
Cancer Med; 2020 Feb; 9(4):1400-1408. PubMed ID: 31891228
[TBL] [Abstract][Full Text] [Related]
14. Low-dose, prophylactic, extended-field, intensity-modulated radiotherapy plus concurrent weekly cisplatin for patients with stage IB2-IIIB cervical cancer, positive pelvic lymph nodes, and negative para-aortic lymph nodes.
Liang JA; Chen SW; Hung YC; Yeh LS; Chang WC; Lin WC; Chang YY
Int J Gynecol Cancer; 2014 Jun; 24(5):901-7. PubMed ID: 23975081
[TBL] [Abstract][Full Text] [Related]
15. Comparison of conventional fractionation (five fractions per week) and altered fractionation (six fractions per week) in stage I and II squamous cell carcinoma of oropharynx: An institutional study.
Poddar J; Sharma AD; Kunikullaya SU; Neema JP
Indian J Cancer; 2017; 54(1):6-10. PubMed ID: 29199652
[TBL] [Abstract][Full Text] [Related]
16. Phase 2 Randomized Controlled Trial of Radiation Therapy Plus Concurrent Interferon-Alpha and Retinoic Acid Versus Cisplatin for Stage III Cervical Carcinoma.
Basu P; Jenson AB; Majhi T; Choudhury P; Mandal R; Banerjee D; Biswas J; Pan J; Rai SN; Ghim SJ; Miller D
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):102-110. PubMed ID: 26700705
[TBL] [Abstract][Full Text] [Related]
17. Impact of Treatment Time on Chemoradiotherapy in Locally Advanced Cervical Carcinoma.
Pathy S; Kumar L; Pandey RM; Upadhyay A; Roy S; Dadhwal V; Madan R; Chander S
Asian Pac J Cancer Prev; 2015; 16(12):5075-9. PubMed ID: 26163644
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled study comparing simultaneous modulated accelerated radiotherapy versus simultaneous integrated boost intensity modulated radiotherapy in the treatment of locally advanced head and neck cancer.
Tandon S; Gairola M; Ahlawat P; Rawat S; Aggarwal A; Sharma K; Tiwari S; Karimi AM; Muttagi V; Sachdeva N; Bhushan M
J Egypt Natl Canc Inst; 2018 Sep; 30(3):107-115. PubMed ID: 29960876
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of semiextended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients: An observational study of 10-year experience.
Lee J; Lin JB; Sun FJ; Chen YJ; Chang CL; Jan YT; Wu MH
Medicine (Baltimore); 2017 Mar; 96(10):e6158. PubMed ID: 28272204
[TBL] [Abstract][Full Text] [Related]
20. Multi-institutional Observational Study of Prophylactic Extended-Field Concurrent Chemoradiation Therapy Using Weekly Cisplatin for Patients With Pelvic Node-Positive Cervical Cancer in East and Southeast Asia.
Wakatsuki M; Kato S; Ohno T; Banu PA; Hoang NC; Yadamsuren E; Supriana N; Cao J; Devi CRB; Calaguas MJ; Chansilpa Y; Cho CK; Adylkhanov T; Okonogi N; Nakano T; Tsujii H
Int J Radiat Oncol Biol Phys; 2019 Sep; 105(1):183-189. PubMed ID: 31125594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
